Pharmaceutical Executive January 13, 2026
Key Takeaways
- Biogen is diversifying its pipeline to reduce reliance on blockbuster drugs, launching therapies in Alzheimer’s, Friedreich Ataxia, postpartum depression, and ALS.
- The company achieved significant cost savings through organizational redesign, supporting its strategic shift beyond multiple sclerosis treatments.
- Biogen’s late-stage pipeline includes 10 phase three programs and five new product launches, though early-stage R&D needs strengthening.
- The European Commission approved a high-dose regimen of Spinraza for spinal muscular atrophy, underscoring Biogen’s commitment to evolving patient care.
The company plans to expand its pipeline and be less reliant on a small number of blockbuster drugs.
During the first day of the 44th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With the looming...
Today's Sponsors
Today's Sponsor